MDL 28170: Selective Calpain and Cathepsin B Inhibitor for Neuroprotection and Disease Models

Executive Summary: MDL 28170 (Calpain and Cathepsin B Inhibitor, Selective) is a nanomolar-potency, cell-permeable inhibitor targeting cysteine proteases calpain (Ki = 10 nM) and cathepsin B (Ki = 25 nM) with high selectivity and validated specificity in vitro and in vivo [APExBIO]. This inhibitor rapidly penetrates the blood-brain barrier and inhibits brain cysteine protease activity after systemic administration (Zhang et al., 2025). MDL 28170 is effective in neuroprotection, notably restoring BDNF/TrkB signaling and preventing cognitive deficits in rodent models of maternal surgery-induced neurodevelopmental injury. It is insoluble in water but readily dissolves in DMSO and ethanol (≥16.75 mg/mL and ≥25.05 mg/mL, respectively). The compound is widely adopted in apoptosis assays, ischemia-reperfusion injury, parasitology, and cardiac protection studies.

Biological Rationale

Calpains and cathepsin B are cysteine proteases implicated in pathological proteolysis during apoptosis, neurodegeneration, ischemia-reperfusion injury, and parasitic infections [CathepsinsInhibitor.com]. Excessive calpain activation leads to breakdown of cytoskeletal and synaptic proteins, contributing to neuronal loss and cognitive impairment. In the context of maternal non-obstetric surgery, increased calpain disrupts hippocampal BDNF/TrkB signaling, impeding synaptic plasticity and neurodevelopment (Zhang et al., 2025). Cathepsin B also mediates lysosomal leakage and apoptosis, further exacerbating cellular damage. Inhibiting these proteases is a validated strategy for limiting injury and preserving function in disease models [ca074.com].

Mechanism of Action of MDL 28170 (Calpain and Cathepsin B Inhibitor, Selective)

MDL 28170 is a reversible, membrane-permeable inhibitor that binds the catalytic cysteine residues at the active sites of calpain and cathepsin B, blocking substrate access and proteolytic activity. Its selectivity profile is defined by nanomolar Ki values for calpain (10 nM) and cathepsin B (25 nM), while showing no inhibition of trypsin-like serine proteases at concentrations up to 1 μM [APExBIO]. MDL 28170 rapidly crosses the blood-brain barrier, enabling effective inhibition of brain cysteine proteases after systemic dosing. This blockade prevents calpain-mediated breakdown of cytoskeletal proteins (e.g., spectrin), reduces apoptotic cell death, and preserves synaptic markers such as PSD95 and NeuN (Zhang et al., 2025). In cardiac tissue, inhibition of calpain protects sarcomere integrity and limits myocardial injury during ischemia-reperfusion.

Evidence & Benchmarks

• MDL 28170 (A4412, APExBIO) exhibits a Ki of 10 nM for calpain and 25 nM for cathepsin B in biochemical assays, with no effect on trypsin at 1 μM (APExBIO).
• Systemic administration (ip, 20 mg/kg) in rats achieves significant brain cysteine protease inhibition within 30 minutes (Zhang et al., 2025).
• Postnatal MDL 28170 administration after maternal surgery restores BDNF/TrkB signaling, NeuN/PSD95 expression, and dendritic spine density, improving spatial learning and memory in offspring (Zhang et al., 2025).
• MDL 28170 reduces infarct size and myocardial injury in ischemia-reperfusion models by preserving sarcomere architecture (ca-074me.com).
• Schwann cells show increased survival under oxidative stress when treated with MDL 28170 (in vitro, 10 μM) (APExBIO).
• Trypanosoma cruzi trypomastigotes exhibit dose-dependent viability reduction in vitro (IC50 ≈ 4 μM) with MDL 28170 (CathepsinsInhibitor.com).

Applications, Limits & Misconceptions

MDL 28170 is validated in apoptosis assays, neuroprotection research, ischemia-reperfusion injury, and parasitology. It is a reference standard in studies dissecting calpain-mediated proteolysis, BDNF/TrkB pathway modulation, and caspase-independent cell death. Compared to prior overviews (e.g., MDL 28170: Selective Calpain and Cathepsin B Inhibitor for Apoptosis and Neuroprotection), this article clarifies mechanistic outcomes in maternal neurodevelopmental models. For scenario-guided workflow recommendations, see the Scenario-Driven Solutions article; here, we extend to comparative efficacy and translational outlooks.

Common Pitfalls or Misconceptions

• MDL 28170 does not inhibit serine proteases (e.g., trypsin, chymotrypsin) at relevant concentrations (≤1 μM).
• Water insolubility necessitates DMSO or ethanol as solvents; aqueous stocks are not stable.
• Chronic or high-dose in vivo use may elicit off-target effects not observed in standard acute models.
• MDL 28170 is not suitable as a therapeutic drug for human use; it is intended for research applications only.
• Long-term storage of prepared solutions is not recommended due to hydrolytic degradation.

Workflow Integration & Parameters

MDL 28170 is supplied by APExBIO as a solid (SKU A4412) and should be stored at -20°C. Prepare fresh stock solutions in DMSO (≥16.75 mg/mL) or ethanol (≥25.05 mg/mL, ultrasonic assistance recommended). For cell culture, final DMSO concentration should not exceed 0.1–0.2%. In rodent models, effective systemic dosing ranges from 10 to 20 mg/kg (ip), yielding rapid brain penetration and target engagement (Zhang et al., 2025). Avoid repeated freeze-thaw cycles. For comparative mechanistic context, see the MDL 28170: Selective Calpain Inhibitor for Neuroprotection article, which this overview updates with new neurodevelopmental data.

Conclusion & Outlook

MDL 28170 (Calpain and Cathepsin B Inhibitor, Selective) is a validated, nanomolar-potency tool for dissecting cysteine protease biology in advanced disease models. Its unique combination of selectivity, cell permeability, and blood-brain barrier penetration underpins its widespread adoption for apoptosis, neuroprotection, ischemic injury, and parasitology research. Ongoing findings—such as those in BDNF/TrkB-mediated neurodevelopmental protection—position MDL 28170 as indispensable for mechanistic, translational, and workflow-driven experimentation. For full specifications or to order the A4412 kit, visit APExBIO's MDL 28170 product page.